Effect of Long Term Trimetazidine Treatment on Myocardial Final Fibrosis for Acute Myocardial Infarction
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 194
- 试验地点
- 2
- 主要终点
- myocardial fibrosis measured by cardiac magnetic resonance imaging
研究概览
简要总结
Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real world clinical practice. In this observational study, we investigated the effect of long-term treatment with trimetazidine on the final extent of myocardial fibrosis measured by cardiac magnetic resonance 6 months after infarction in real world clinical practice.
详细描述
This study is an prospective observational real-world clinical research. We evaluated the effect of long term trimetazidine treatment after the primary percutaneous coronary intervention (PCI), the myocardial infarction size in STEMI patients could be further reduced by metabolic regulation therapy. This study contributes to the development of standardized treatment procedure for STEMI patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed STEMI patients within one day after reperfusion threapy; Have performed the primary PCI procedure; Sign the informed consent form for this cohort study
排除标准
- •Mechanical complications; Cardiogenic shock; Malignant tumors, severe infection, hepatic or renal failure, respiratory failure, or other short-term progressive diseases
结局指标
主要结局
myocardial fibrosis measured by cardiac magnetic resonance imaging
时间窗: 6 months after infarction
Delayed enhancement of cardiac magnetic resonance imaging showed the myocardial fibrosis after infarction
次要结局
未报告次要终点
研究者
Qian geng
MD
Chinese PLA General Hospital